DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio
Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) --
Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions.
Expanding statins portfolio
With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP apart from competitors is its backward integration and secure control of its supply chain in the production of its finished drug products.
In 2012, DSP was the first pharmaceutical manufacturer worldwide to offer generic Atorvastatin active pharmaceutical ingredients (APIs) under a Certificate of Suitability (CEP). Since 2014, DSP has produced enzymatic Atorvastatin API in its state-of-the-art facility in Toansa, India for third party customers, as well as now for its own new finished dosage formulation.
BU Director for Drug Products, Lucas Wiarda stated: "In utilizing our own in-house APIs to develop our finished dosage Atorvastatin, we deliver to both existing and future customers a product that offers unparalleled reliability. Customers can trust that DSP's Atorvastatin is comprised of APIs from our own supply chain, which were first developed back in 2012. Our statins portfolio now contains the two most popular products in the fight against cardiovascular disease and high cholesterol, and showcases our commitment to providing outstanding generic statins in this highly-competitive market."
In bringing Atorvastatin finished dosage formulation to the marketplace, DSP continues to deliver on its brand promise to customers, with Quality via world-class, differentiated active pharmaceutical ingredients, Reliability through an internal supply chain for all elements of producing a finished dosage product, and Sustainability at the forefront of its drug product production, using patented enzymatic technology which ensures an unmatched eco-friendly production process.
DSP holds an electronic Common Technical Document (eCTD) dossier for Atorvastatin finished dosage formulations (in 10, 20, 40, and 80 mg film-coated tablets, along with additional 30 and 60 mg strengths complementing the standard dosage range) suitable for climate Zone II (Mediterranean and subtropical zone), with a 24-month shelf life. DSP is currently pursuing further stability studies to expand its filings to additional climate zones.
About DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Geoff Vokes, Senior External Communications Manager. E-Mail: firstname.lastname@example.org
Geoff Vokes DSM Sinochem Pharmaceuticals email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM Sinochem Pharmaceuticals via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership18.7.2018 14:00 | Pressmeddelande
RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership. Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies. Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism. Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the indu
Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)18.7.2018 13:30 | Pressmeddelande
Ongoing Alzheimer's disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer's disease clinical development portfolio including aducanumab, elenbecestat, and BAN2401 Data underscore Biogen's long-term commitment to furthering Alzheimer's disease research and treatment, with a focus on patients with early stage disease CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) announced it will present data from its Alzheimer's disease clinical development portfolio at the upcoming Alzheimer's Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen's research programs targeting several of the identified causes of Alzheimer's disease, focusing on early-stage disease. "The data to be presented at AAIC exemplify our belief that treatments are needed at the earliest stages of Alzheimer's disease to impact the underlying pathophysiology and delay disease p
SEMAFO Provides Notice of Second Quarter 2018 Results Release and Conference Call18.7.2018 13:00 | Pressmeddelande
MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF)(OMX:SMF) invites you to participate in a conference call on August 8, 2018 at 08:00 AM EST with senior management during which they will review the Corporation's second quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the second quarter 2018 will be released on August 7 following TSX close and will be available in the "Investor Relations" section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO's website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 7370499 Expiration: September 08, 2018 About SEMAFO SEMAFO is a Canadi
Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams18.7.2018 12:00 | Pressmeddelande
Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe. With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets. DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and De
Cryptomining Replaces Ransomware as Most Popular Cybercrime Malware18.7.2018 09:00 | Pressmeddelande
Analysis of vulnerability and threat trends shows cryptomining malware dominates threat landscape in the first half of 2018 SAN JOSE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, announced today the release of its mid-year update to the Vulnerability and Threat Trends Report which analyzes vulnerabilities, exploits and threats in play. The report, compiled by the team of security analysts at the Skybox® Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape. The mid-year update explores trends observed from January to June of 2018. One of the most significant findings is the replacement of ransomware as the cybercriminal tool of choice with cryptomining malware. In the last six months of 2017, ransomware accounted for 32 percent of attacks, while malicious cryptominers accounted for seven percent. By the first half of 2018, the figures had switched almost exactly
GridGain® Continues In-Memory Computing Industry Leadership in 201818.7.2018 09:00 | Pressmeddelande
GridGain Continues Rapid Growth, Delivers Product Innovations, Hosts Vital Industry Conferences and Earns Top Industry Accolades FOSTER CITY, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today announced continuing strong momentum for the first half of 2018. Key achievements during the first half of the year included more new customer wins in the first half of 2018 than in all of 2017, launching major new products including GridGain Professional Edition 2.4 and GridGain Cloud, winning several top industry accolades, and driving continued growth of the popular In-Memory Computing Summit® in Europe. Growth New customer acquisition surged during the first half of 2018 with the company acquiring 40 percent more new customers than were signed in all of 2017. New customers acquired in 2018 include leading companies in financial services, transportation, telecommunications, retail, healthcar
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum